EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Mesenchymal Stromal Cell-Based Therapies in Sepsis-Induced Acute Lung and Kidney Injury: Current Advances and Perspectives

Carla M da Silva, Mayck M A da Silva iD, Marcelo M Morales iD

International Journal of Molecular Sciences · 04.08.2026 · 27 (15) · 6990

DOI: 10.3390/ijms27156990 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 04.08.2026. Verfasst von Carla M da Silva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21…. Hauptthemen laut MEDLINE: Sepsis, Mesenchymal Stem Cell Transplantation, Acute Kidney Injury, Mesenchymal Stem Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, National Institute of Gene Therapy (INTERGEN), Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sepsis is a life-threatening syndrome characterized by severe immune dysregulation, frequently culminating in acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). Current supportive therapies fail to reverse the underlying pathophysiological damage. However, mesenchymal stromal cells (MSCs) have emerged as a promising therapeutic frontier due to their robust immunomodulatory, anti-inflammatory, and tissue-regenerative properties. Despite compelling preclinical evidence, translating these benefits into consistent clinical efficacy remains a major challenge. This review critically examines the biological and anatomical barriers limiting the efficacy of MSCs, particularly the pulmonary first-pass effect, which restricts the systemic delivery of viable cells to distant organs such as the kidneys. To overcome these physical limitations, we highlight the recent paradigm shift toward nanoscale, cell-free therapies, specifically MSC-derived extracellular vesicles (MSC-EVs). EVs effectively bypass pulmonary sequestration and thromboembolic risks, exerting their potent therapeutic effects through the horizontal transfer of bioactive cargo, notably microRNAs, to reprogram cellular fate and restore immune homeostasis. We also discuss the critical need for rigorous clinical trial designs, scalable good manufacturing practice protocols, and the integration of a precision medicine approach. Ultimately, incorporating validated biomarkers for targeted patient stratification will be the decisive step in unlocking the full therapeutic potential of MSCs and their derivatives in critical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SepsisMesenchymal Stem Cell TransplantationAcute Kidney InjuryMesenchymal Stem CellsAcute Lung InjuryHumansAnimalsExtracellular VesiclesCell- and Tissue-Based Therapy

Stichwörter der Autor:innen

cell therapymesenchymal stromal cellsepsis

Autor:innen und Institutionen

  • Laboratory of Cellular and Molecular Physiology, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.
  • Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, RJ, Brazil.

ORCID-Profile: Mayck M A da Silva, Marcelo M Morales

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • National Institute of Gene Therapy (INTERGEN)
  • Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro (FAPERJ)
  • Brazilian Council for Scientific and Technological Development
  • the Rio de Janeiro State Research Foundation
  • the Department of Science and Technology/Brazilian Ministry of Health
  • the Coordination for the Improvement of Higher Education Personnel
  • the National Institute of Advanced Technologies in Diagnosis and Prognosis of Chronic and Neglected Diseases

Zitieren

APA

da Silva, C. M., da Silva, M. M. A., & Morales, M. M. (2026). Mesenchymal Stromal Cell-Based Therapies in Sepsis-Induced Acute Lung and Kidney Injury: Current Advances and Perspectives. International Journal of Molecular Sciences, 27(15), 6990. https://doi.org/10.3390/ijms27156990

Vancouver

da Silva CM, da Silva MMA, Morales MM. Mesenchymal Stromal Cell-Based Therapies in Sepsis-Induced Acute Lung and Kidney Injury: Current Advances and Perspectives. International Journal of Molecular Sciences. 2026;27(15):6990. doi:10.3390/ijms27156990

BibTeX
@article{daSilva2026,
  author = {da Silva, Carla M and da Silva, Mayck M A and Morales, Marcelo M},
  title = {Mesenchymal Stromal Cell-Based Therapies in Sepsis-Induced Acute Lung and Kidney Injury: Current Advances and Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {15},
  pages = {6990},
  doi = {10.3390/ijms27156990}
}
Kostenlos starten →